FDA Clears Sunharbo to Help Prevent Repeat Strokes
U.S. drug regulators authorized Sunharbo, or asundexian, for certain adults who recently had an ischemic stroke caused by a clot not originating in the heart, or a high-risk transient ischemic attack. The 50-milligram pill is taken once daily with antiplatelet treatment such as aspirin. It is the first approved drug designed to block factor XIa, a protein involved in clot formation.
The decision followed a randomized phase 3 trial involving 12,327 patients in 37 countries. Over an average of 14.2 months, ischemic strokes occurred in 6.6% of participants taking asundexian alongside antiplatelet therapy, compared with 8.8% of those given a placebo and the same type of therapy. The relative reduction was 26%.
Major bleeding did not rise significantly across the full study group, but gastrointestinal bleeding was more common with the drug. Among participants aged over 75, serious bleeding was more likely in the initial 90 days. The combined rate of heart-related death, heart attack or stroke was 9.2% with asundexian and 11.1% with placebo; deaths from any cause were 10.5% and 12.3%, respectively.
The trial, funded by manufacturer Bayer, excluded people with certain cardiac disorders and patients whose strokes were more severe. Results were published in the November 9 issue of the medical journal NEJM. Cardiologist Richard Kovacs said the drug is not intended for strokes linked to atrial fibrillation or a heart valve problem, and patients should discuss it with their clinicians shortly following a stroke. Trial treatment began within 72 hours. Researchers called for longer studies, including in older adults and people with more severe strokes. Lifestyle measures such as stopping smoking, managing cholesterol, eating well and exercising also remain part of prevention.
Reported by Fox News, FOX 13 Seattle.







